Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes.

Valoti E, Noris M, Perna A, Rurali E, Gherardi G, Breno M, Parvanova Ilieva A, Petrov Iliev I, Bossi A, Trevisan R, Dodesini AR, Ferrari S, Stucchi N, Benigni A, Remuzzi G, Ruggenenti P.

Front Genet. 2019 Jul 26;10:681. doi: 10.3389/fgene.2019.00681. eCollection 2019.

PMID:
31428128
2.

Erratum to: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Aug 9. pii: gfz137. doi: 10.1093/ndt/gfz137. [Epub ahead of print] No abstract available.

PMID:
31397476
3.

Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab.

Podestà MA, Gennarini A, Portalupi V, Rota S, Alessio MG, Remuzzi G, Ruggenenti P.

Nephron. 2019 Jul 23:1-6. doi: 10.1159/000501858. [Epub ahead of print]

PMID:
31336376
4.

A First Step toward a New Approach to Treating Membranous Nephropathy.

Ruggenenti P, Remuzzi G.

N Engl J Med. 2019 Jul 4;381(1):86-88. doi: 10.1056/NEJMe1906666. No abstract available.

PMID:
31269372
5.

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.

Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE; ANSWER Study Organization.

Am J Kidney Dis. 2019 Apr 23. pii: S0272-6386(19)30136-2. doi: 10.1053/j.ajkd.2019.01.029. [Epub ahead of print]

PMID:
31027883
6.

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, Pisani A, Riccio E, Imbriaco M, Dugo M, Morana G, Granata A, Figuera M, Gaspari F, Carrara F, Rubis N, Villa A, Gamba S, Prandini S, Cortinovis M, Remuzzi A, Remuzzi G; ALADIN 2 Study Group.

PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.

7.

C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.

Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, Rubis N, Peraro F, Gaspari F, Pasini A, Rigotti A, Lerchner RM, Santoro D, Pisani A, Pasi A, Remuzzi G; EAGLE Study Group.

Am J Kidney Dis. 2019 Aug;74(2):224-238. doi: 10.1053/j.ajkd.2018.12.046. Epub 2019 Mar 28.

PMID:
30929851
8.

Erratum.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 28. pii: gfz047. doi: 10.1093/ndt/gfz047. [Epub ahead of print] No abstract available.

PMID:
30820538
9.

Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.

Ruggenenti P, Trillini M, P Barlovic D, Cortinovis M, Pisani A, Parvanova A, Iliev IP, Ruggiero B, Rota S, Aparicio MC, Perna A, Peraro F, Diadei O, Gaspari F, Carrara F, Stucchi N, Martinetti D, Janez A, Gregoric N, Riccio E, Bossi AC, Trevisan R, Manunta P, Battaglia G, David S, Aucella F, Belviso A, Satta A, Remuzzi G; VALID Study Organization.

Diabetes Obes Metab. 2019 May;21(5):1177-1190. doi: 10.1111/dom.13639. Epub 2019 Feb 22.

PMID:
30793466
10.

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):208-230. doi: 10.1093/ndt/gfy407.

PMID:
30753708
11.

Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research.

Ruggenenti P, Remuzzi G.

Am J Nephrol. 2019;49(2):143-145. doi: 10.1159/000496275. Epub 2019 Jan 24. No abstract available.

12.

Author Correction: Estimated GFR: time for a critical appraisal.

Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jiménez A, de Vries APJ, Torres A, Gaspari F, Remuzzi G.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0105-4.

PMID:
30563967
13.

Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients.

Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P.

Data Brief. 2018 Nov 14;21:2075-2081. doi: 10.1016/j.dib.2018.11.041. eCollection 2018 Dec.

14.

Estimated GFR: time for a critical appraisal.

Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jiménez A, de Vries APJ, Torres A, Gaspari F, Remuzzi G.

Nat Rev Nephrol. 2019 Mar;15(3):177-190. doi: 10.1038/s41581-018-0080-9. Review. Erratum in: Nat Rev Nephrol. 2018 Dec 18;:.

PMID:
30518813
15.

Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.

Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P; ALADIN-Cardiovascular Study Group.

Int J Cardiol. 2019 Jan 15;275:145-151. doi: 10.1016/j.ijcard.2018.10.063. Epub 2018 Oct 22.

PMID:
30509370
16.

Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.

Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggenenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P.

Diabet Med. 2018 Oct;35(10):1375-1382. doi: 10.1111/dme.13669. Epub 2018 Jun 6.

PMID:
29781558
17.

Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience.

Gaspari F, Thakar S, Carrara F, Perna A, Trillini M, Aparicio MC, Diadei O, Ferrari S, Cannata A, Stucchi N, Ruggenenti P, Remuzzi G, Perico N.

Nephron. 2018;140(1):1-8. doi: 10.1159/000489898. Epub 2018 May 17.

PMID:
29772565
18.

Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.

Parvanova A, Trillini M, Podestà MA, Iliev IP, Aparicio C, Perna A, Peraro F, Rubis N, Gaspari F, Cannata A, Ferrari S, Bossi AC, Trevisan R, Parameswaran S, Chávez-Iñiguez JS, Masnic F, Seck SM, Jiamjariyaporn T, Cortinovis M, Perico L, Sharma K, Remuzzi G, Ruggenenti P, Warnock DG.

J Endocr Soc. 2018 Mar 22;2(5):420-436. doi: 10.1210/js.2017-00426. eCollection 2018 May 1.

19.

Invited letter in response to: "Is the kidney donor profile index (KDPI) universal or UNOS-specific?"

Ruggenenti P, Remuzzi G.

Am J Transplant. 2018 Apr;18(4):1033-1034. doi: 10.1111/ajt.14652. Epub 2018 Feb 3. No abstract available.

20.

Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?

Noris M, Ruggenenti P, Remuzzi G.

Am J Kidney Dis. 2017 Dec;70(6):754-757. doi: 10.1053/j.ajkd.2017.08.005. No abstract available.

PMID:
29169515
21.

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.

Parvanova A, Trillini M, Podestà MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016.

Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. doi: 10.1016/S2213-8587(17)30359-5. Epub 2017 Nov 2.

PMID:
29104158
22.

Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study.

Ruggenenti P, Silvestre C, Boschiero L, Rota G, Furian L, Perna A, Rossini G, Remuzzi G, Rigotti P.

Am J Transplant. 2017 Dec;17(12):3159-3171. doi: 10.1111/ajt.14459. Epub 2017 Sep 15.

23.

Treatment of membranous nephropathy: time for a paradigm shift.

Ruggenenti P, Fervenza FC, Remuzzi G.

Nat Rev Nephrol. 2017 Sep;13(9):563-579. doi: 10.1038/nrneph.2017.92. Epub 2017 Jul 3. Review.

PMID:
28669992
24.

Dual renin-angiotensin system blockade for nephroprotection.

Ruggenenti P.

Nephrol Ther. 2017 Apr;13 Suppl 1:S43-S45. doi: 10.1016/j.nephro.2017.02.006.

PMID:
28577742
25.

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G.

J Am Soc Nephrol. 2017 Sep;28(9):2729-2737. doi: 10.1681/ASN.2016091022. Epub 2017 May 9.

26.

ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease.

Perico N, Ruggenenti P, Remuzzi G.

Curr Opin Pharmacol. 2017 Apr;33:34-40. doi: 10.1016/j.coph.2017.03.006. Epub 2017 May 5. Review.

PMID:
28482281
27.

Preventing nephropathy in type 2 diabetes.

Ruggenenti P.

G Ital Nefrol. 2016 Malattie Metaboliche e Rene;33(S68). pii: gin/33.S68.14. No abstract available.

28.

Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients.

Cortinovis M, Gotti E, Trillini M, Carrara F, Gaspari F, Ruggenenti P, Remuzzi G, Perico N.

Nephron. 2017;135(3):173-180. doi: 10.1159/000453671. Epub 2016 Dec 10.

PMID:
27941326
29.

Achieving remission of proteinuria in childhood CKD.

Ruggenenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G.

Pediatr Nephrol. 2017 Feb;32(2):321-330. doi: 10.1007/s00467-016-3495-1. Epub 2016 Oct 4.

30.

Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?

Delanaye P, Melsom T, Ebert N, Bäck SE, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Gaspari F.

Clin Kidney J. 2016 Oct;9(5):700-4. doi: 10.1093/ckj/sfw071. Epub 2016 Sep 9.

31.

Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?

Delanaye P, Ebert N, Melsom T, Gaspari F, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Bäck SE.

Clin Kidney J. 2016 Oct;9(5):682-99. doi: 10.1093/ckj/sfw070. Epub 2016 Aug 23.

32.

Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial.

Ruggenenti P, Abbate M, Ruggiero B, Rota S, Trillini M, Aparicio C, Parvanova A, Petrov Iliev I, Pisanu G, Perna A, Russo A, Diadei O, Martinetti D, Cannata A, Carrara F, Ferrari S, Stucchi N, Remuzzi G, Fontana L; C.RE.S.O. Study Group.

Diabetes. 2017 Jan;66(1):75-86. doi: 10.2337/db16-0607. Epub 2016 Sep 15.

33.

Progression, Remission and Regression of Chronic Renal Diseases.

Cortinovis M, Ruggenenti P, Remuzzi G.

Nephron. 2016;134(1):20-4. doi: 10.1159/000445844. Epub 2016 Apr 21. Review.

34.

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.

Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.

35.

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.

Lindhardt M, Persson F, Currie G, Pontillo C, Beige J, Delles C, von der Leyen H, Mischak H, Navis G, Noutsou M, Ortiz A, Ruggenenti PL, Rychlik I, Spasovski G, Rossing P.

BMJ Open. 2016 Mar 2;6(3):e010310. doi: 10.1136/bmjopen-2015-010310.

36.

Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.

Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G; SIRENA 2 Study Group.

Clin J Am Soc Nephrol. 2016 May 6;11(5):785-94. doi: 10.2215/CJN.09900915. Epub 2016 Feb 22.

37.

Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.

Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P; ALADIN Study Group.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1022-1030.e4. doi: 10.1016/j.cgh.2015.12.049. Epub 2016 Feb 1.

PMID:
26844873
38.

RAS blockade: Nephroprotection by dual RAS blockade--a welcome back.

Ruggenenti P, Remuzzi G.

Nat Rev Nephrol. 2015 Sep;11(9):507-8. doi: 10.1038/nrneph.2015.132. Epub 2015 Aug 4. No abstract available.

PMID:
26241020
39.

Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.

Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries AP; ERA-EDTA diabesity working group.

Lancet Diabetes Endocrinol. 2015 May;3(5):382-91. doi: 10.1016/S2213-8587(15)00094-7.

PMID:
25943757
40.

Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?

Ruggenenti P, Remuzzi G.

Eur J Heart Fail. 2015 May;17(5):468-71. doi: 10.1002/ejhf.267. No abstract available.

41.

A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.

Daina E, Cravedi P, Alpa M, Roccatello D, Gamba S, Perna A, Gaspari F, Remuzzi G, Ruggenenti P.

Nephron. 2015;130(1):13-20. doi: 10.1159/000381480. Epub 2015 Apr 21.

42.

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G.

J Am Soc Nephrol. 2015 Oct;26(10):2545-58. doi: 10.1681/ASN.2014070640. Epub 2015 Mar 24.

43.

Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.

Gentile G, Somma C, Gennarini A, Mastroluca D, Rota G, Lacanna F, Locatelli B, Remuzzi G, Ruggenenti P.

Am J Nephrol. 2015;41(1):16-27. doi: 10.1159/000371728. Epub 2015 Jan 23.

PMID:
25612603
44.

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.

Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.

J Am Soc Nephrol. 2015 Aug;26(8):1999-2010. doi: 10.1681/ASN.2014050423. Epub 2015 Jan 14.

45.

Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.

Gentile G, Remuzzi G, Ruggenenti P.

Nephron. 2015;129(1):39-41. doi: 10.1159/000368331. Epub 2014 Dec 16. Review.

46.

Rituximab in primary membranous nephropathy: first-line therapy, why not?

Cravedi P, Remuzzi G, Ruggenenti P.

Nephron Clin Pract. 2014;128(3-4):261-9. doi: 10.1159/000368589. Epub 2014 Nov 22. Review.

47.

Novel effective drugs for diabetic kidney disease? or not?

Gentile G, Mastroluca D, Ruggenenti P, Remuzzi G.

Expert Opin Emerg Drugs. 2014 Dec;19(4):571-601. doi: 10.1517/14728214.2014.979151. Epub 2014 Nov 7. Review.

PMID:
25376947
48.

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N.

J Am Soc Nephrol. 2015 May;26(5):1205-14. doi: 10.1681/ASN.2013111185. Epub 2014 Sep 5.

49.

Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab.

Marasà M, Cravedi P, Ruggiero B, Ruggenenti P.

BMJ Case Rep. 2014 Aug 25;2014. pii: bcr2014205507. doi: 10.1136/bcr-2014-205507.

50.

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G.

Blood. 2014 Sep 11;124(11):1715-26. doi: 10.1182/blood-2014-02-558296. Epub 2014 Jul 18.

Supplemental Content

Loading ...
Support Center